mAb |
Position |
B.1 |
BA.1 |
BA.4 / BA.5 |
BA.4.6 |
BA.2.75.2 |
BJ.1 |
BQ.1.1 |
Remarks |
Casirivimab (single mAb) |
486* |
|
|
V |
V |
S |
|
V |
Mutation at the position for BA.4/BA.5 (486V), BA.4.6(486V),
BQ.1.1(486V) and BA.2.75.2(486S) strongly correlates with higher EC50
values (>10K indicating neutralization
escape) |
|
490 |
|
|
|
|
|
V |
|
|
|
493* |
|
R |
|
|
|
R |
|
|
|
496* |
|
S |
|
|
|
|
|
|
|
EC50 (ng/ml) |
21 |
1890 |
>50000 |
>50000 |
>50000 |
880 |
>50000 |
|
Imdevimab (single mAbs) |
346 |
|
|
|
T |
T |
T |
T |
Mutation at the position for BA.1(446S), BQ.1.1(346T), BA.2.75.2 (446S
& 346T), BJ.1 (446S & 346T) strongly correlates with higher EC50
values (>10K indicating neutralization escape). Mutation at
position for BA.4.6 (346T) strongly correlates with higher EC50 values
(1000-10K indicating poor neutralization) |
|
444 |
|
|
|
|
|
|
T |
|
|
445 |
|
|
|
|
|
P |
|
|
|
446* |
|
S |
|
|
S |
S |
|
|
|
EC50 (ng/ml) |
19 |
>50000 |
994 |
2109 |
>50000 |
>50000 |
>50000 |
|
Cocktail mAbs |
EC50 (ng/ml) |
9 |
3642 |
2611 |
5395 |
>50000 |
2456 |
>50000 |
|
Bamlanivimab (single mAb) |
452 |
|
|
R |
R |
|
|
R |
No
correlation established as all omicron sublineage show higher EC50
values (>10K indicating neutralization
espcape) |
|
482 |
|
|
|
|
S |
|
|
|
|
483 |
|
|
|
|
|
A |
|
|
|
486* |
|
|
V |
V |
S |
|
V |
|
|
490 |
|
|
|
|
|
V |
|
|
|
493* |
|
R |
|
|
|
R |
|
|
|
EC50 (ng/ml) |
16 |
>50000 |
>50000 |
>50000 |
>50000 |
>50000 |
>50000 |
|
Etesevimab (single mAb) |
405 |
|
|
N |
N |
N |
N |
N |
No
correlation established as all omicron sublineage show higher EC50
values (>10K indicating neutralization
espcape) |
|
408 |
|
|
S |
S |
S |
S |
S |
|
|
460 |
|
|
|
|
K |
|
K |
|
|
486* |
|
|
V |
V |
S |
|
V |
|
|
490 |
|
|
|
|
|
V |
|
|
|
493* |
|
R |
|
|
|
R |
|
|
|
EC50 (ng/ml) |
53 |
>50000 |
>50000 |
>50000 |
>50000 |
>50000 |
>50000 |
|
Cocktail mAbs |
EC50 (ng/ml) |
18 |
>50000 |
>50000 |
>50000 |
>50000 |
>50000 |
>50000 |
|
Cilgavimab (single mAb) |
346 |
|
|
|
T |
T |
T |
T |
Mutation at position for BA.4.6(346T), BA.2.75.2(346T), BJ.1(346T) and
BQ.1.1(346T) strongly correlates with higher EC50 values
(>10K indicating neutralization espcape) |
|
444 |
|
|
|
|
|
|
T |
|
|
445 |
|
|
|
|
|
P |
|
|
|
446* |
|
S |
|
|
S |
S |
|
|
|
452 |
|
|
R |
R |
|
|
R |
|
|
490 |
|
|
|
|
|
V |
|
|
|
493* |
|
R |
|
|
|
R |
|
|
|
EC50 (ng/ml) |
37 |
2658 |
88 |
24200 |
>50000 |
>50000 |
>50000 |
|
Tixagevimab (single mAb) |
486* |
|
|
V |
V |
S |
|
V |
Mutation at position for BA.4/BA.5(486V), BA.4.6(486V), BQ.1.1(486V) and
BA.2.75.2(486S) strongly correlates with higher EC50 values
(>10K indicating neutralization espcape) |
|
493* |
|
R |
|
|
|
R |
|
|
|
EC50 (ng/ml) |
7 |
173 |
10090 |
27740 |
>50000 |
304 |
>50000 |
|
Cocktail mAbs |
EC50 (ng/ml) |
7 |
97 |
155 |
7131 |
>50000 |
482 |
>50000 |
|
Amubarvimab (single mAb) |
460 |
|
|
|
|
K |
|
K |
Mutation
at position for BA.2.75.2(460K) and BQ.1.1(460K) strongly correlates
with higher EC50 values (>10K indicating neutralization
escape) |
|
486* |
|
|
V |
V |
S |
|
V |
|
|
493* |
|
R |
|
|
|
R |
|
|
|
EC50 (ng/ml) |
53 |
5641 |
1234 |
1290 |
>50000 |
4762 |
>50000 |
|
Romlusevimab (single mAb) |
339 |
|
D |
D |
D |
H |
H |
D |
Mutation at position for BA.4.6(346T), BA.2.75.2(346T), BJ.1(346T) and
BQ.1.1(346T) strongly correlates with higher EC50 values
(>10K indicating neutralization espcape) |
|
346 |
|
|
|
T |
T |
T |
T |
|
|
EC50 (ng/ml) |
852 |
866 |
8279 |
>50000 |
>50000 |
>50000 |
>50000 |
|
Cocktail mAbs |
EC50 (ng/ml) |
64 |
657 |
1819 |
1015 |
>50000 |
5359 |
>50000 |
|
Regdanvimab (single mAb) |
452 |
|
|
R |
R |
|
|
R |
Mutation
at position for BA.4/BA.5(486V), BA.4.6(486V), BQ.1.1(486V), BA.1(493R)
and BJ.1(493R) strongly correlates with higher EC50 values
(>10K indicating neutralization espcape). |
|
486* |
|
|
V |
V |
S |
|
V |
|
|
490 |
|
|
|
|
|
V |
|
|
|
493* |
|
R |
|
|
|
R |
|
|
|
496* |
|
S |
|
|
|
|
|
|
|
EC50 (ng/ml) |
7 |
>50000 |
>50000 |
>50000 |
6336 |
>50000 |
>50000 |
|
Bebtelovimab (single mAb) |
346 |
|
|
|
T |
T |
T |
T |
One
of the most effective mAb, but no clear correlation established against
mutations for neutralisation escape |
|
444 |
|
|
|
|
|
|
T |
|
|
445 |
|
|
|
|
|
P |
|
|
|
446* |
|
S |
|
|
S |
S |
|
|
|
EC50 (ng/ml) |
5 |
7 |
6 |
7 |
14 |
>50000 |
>50000 |
|
Sotrovimab (single mAb) |
339 |
|
D |
D |
D |
H |
H |
D |
One
of the most effective mAb. However, mutation at the position for BA.4.6
(339D and 346T) and BQ.1.1(339D, 346T and 444T) strongly correlates with
higher EC50 values (>10K indicating neutralization
escape) |
|
346 |
|
|
|
T |
T |
T |
T |
|
|
444 |
|
|
|
|
|
|
T |
|
|
EC50 (ng/ml) |
157 |
833 |
5554 |
13000 |
3239 |
825 |
>50000 |
|
Adintrevimab (single mAb) |
405 |
|
|
N |
N |
N |
N |
N |
Mutation at the position for BA.4/BA.5 (405N and 408S), BA.4.6(405N and
408S), BA.2.75.2(405N and 408S), BJ.1(405N and 408S) and BQ.1.1(405N and
408S) strongly correlates with higher EC50 values (>10K
indicating neutralization escape) |
|
408 |
|
|
S |
S |
S |
S |
S |
|
|
496* |
|
S |
|
|
|
|
|
|
|
EC50 (ng/ml) |
14 |
23 |
>50000 |
>50000 |
>50000 |
>50000 |
>50000 |
|
indicates an increase in EC50 of cocktail mAbs as compared to
single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to
single mAb. = indicates equal EC50 of cocktail mAbs as compared to
single mAb. The first and second arrows indicate a relative change in
EC50 of cocktail mAbs about each mAbs when used solitarily. |
indicates an increase in EC50 of cocktail mAbs as compared to
single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to
single mAb. = indicates equal EC50 of cocktail mAbs as compared to
single mAb. The first and second arrows indicate a relative change in
EC50 of cocktail mAbs about each mAbs when used solitarily. |
indicates an increase in EC50 of cocktail mAbs as compared to
single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to
single mAb. = indicates equal EC50 of cocktail mAbs as compared to
single mAb. The first and second arrows indicate a relative change in
EC50 of cocktail mAbs about each mAbs when used solitarily. |
indicates an increase in EC50 of cocktail mAbs as compared to
single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to
single mAb. = indicates equal EC50 of cocktail mAbs as compared to
single mAb. The first and second arrows indicate a relative change in
EC50 of cocktail mAbs about each mAbs when used solitarily. |
indicates an increase in EC50 of cocktail mAbs as compared to
single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to
single mAb. = indicates equal EC50 of cocktail mAbs as compared to
single mAb. The first and second arrows indicate a relative change in
EC50 of cocktail mAbs about each mAbs when used solitarily. |
indicates an increase in EC50 of cocktail mAbs as compared to
single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to
single mAb. = indicates equal EC50 of cocktail mAbs as compared to
single mAb. The first and second arrows indicate a relative change in
EC50 of cocktail mAbs about each mAbs when used solitarily. |
indicates an increase in EC50 of cocktail mAbs as compared to
single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to
single mAb. = indicates equal EC50 of cocktail mAbs as compared to
single mAb. The first and second arrows indicate a relative change in
EC50 of cocktail mAbs about each mAbs when used solitarily. |
indicates an increase in EC50 of cocktail mAbs as compared to
single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to
single mAb. = indicates equal EC50 of cocktail mAbs as compared to
single mAb. The first and second arrows indicate a relative change in
EC50 of cocktail mAbs about each mAbs when used solitarily. |
indicates an increase in EC50 of cocktail mAbs as compared to
single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to
single mAb. = indicates equal EC50 of cocktail mAbs as compared to
single mAb. The first and second arrows indicate a relative change in
EC50 of cocktail mAbs about each mAbs when used solitarily. |
indicates an increase in EC50 of cocktail mAbs as compared to
single mAb. indicates a decrease in EC50 of cocktail mAbs as compared to
single mAb. = indicates equal EC50 of cocktail mAbs as compared to
single mAb. The first and second arrows indicate a relative change in
EC50 of cocktail mAbs about each mAbs when used
solitarily. |